ACAM2000 (smallpox and mpox replication-competent vaccinia virus vaccine; Emergent BioSolutions) is now FDA-approved as a single percutaneous dose for the prevention of mpox in persons at high risk for mpox virus infection, in addition to the existing indication for smallpox. ACAM2000 was previously authorized for the prevention of mpox under an FDA Emergency Use Authorization. This approval is based on previously available data from human and animal studies that showed ACAM2000 was effective in protecting against mpox virus exposure.
Source: Travax, September 2024.
Related alert: Africa: mpox declared a Public Health Emergency of International Concern (August 2024). See also the vaccines we offer and their prices.
Planning a trip? A pre-travel consultation covers the vaccines, medications, and current health alerts for your itinerary. Book online (opens in a new tab) or call (212) 734-3000.